Results 131 to 140 of about 5,881 (166)
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape. [PDF]
Gay F +39 more
europepmc +1 more source
Circular RNAs (circRNAs) act as a key role in mediating carcinogenesis. Nevertheless, the functions and mechanisms of circRNAs in osteosarcoma (OS) are still not fully understood. In the present study, we aim to investigate the functions of circ-XPO1 in OS and its potential mechanism underlying OS progression.
Lei Shen, Yang Jiang, Yongtao Li
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Targeting XPO1-Dependent Nuclear Export in Cancer
Biochemistry (Moscow), 2022Nucleocytoplasmic transport of macromolecules is tightly regulated in eukaryotic cells. XPO1 is a transport factor responsible for the nuclear export of several hundred protein and RNA substrates. Elevated levels of XPO1 and recurrent mutations have been reported in multiple cancers and linked to advanced disease stage and poor survival.
Alexey V Sorokin +2 more
exaly +3 more sources
XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma [PDF]
Pancreatic adenocarcinoma (PAC) is one of the most aggressive human cancers and new systemic therapies are urgently needed. Exportin-1 (XPO1), which is a member of the importin-β superfamily of karyopherins, is the major exporter of many tumor suppressor proteins that are involved in the progression of PAC.
Daniel Birnbaum +2 more
exaly +4 more sources
Prognostic and therapeutic significance of XPO1 in T-cell lymphoma
Experimental Cell Research, 2022T-cell lymphoma (TCL) is a highly heterogeneous group of invasive non-Hodgkin lymphoma with adverse prognosis and limited treatment options. The relationship between TCL and Exportin-1 (XPO1), a major nuclear export receptor, has not been established yet. We here investigated the prognostic role and therapeutic implication of XPO1 in TCL.
Danian Nie, Yiqing Li
exaly +3 more sources
Redirecting traffic using the XPO1 police
Blood, 2013In this issue of Blood, Walker et al investigate the preclinical potential of KPT-330, an exportin-1 (XPO1, also known as chromosome maintenance protein 1 [CRM1]) inhibitor, against both accelerated phase (AP) and blast crisis chronic myeloid leukemia (CML-BC) and against Philadelphia chromosome-positive (Ph1) acute lymphoblastic leukemia (ALL), all of
Sheela A, Abraham, Tessa L, Holyoake
openaire +2 more sources
Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia
Clinical and Experimental Medicine, 2023Chronic lymphocytic leukemia (CLL) is a subtype of B-cell malignancy with high heterogeneity. XPO1 is highly expressed in many hematological malignancies, which predicts poor prognosis. In the study, we aimed to explore the prognostic role of XPO1 and the therapeutic effect of Selinexor, a selective inhibitor of nuclear export, which targets XPO1.
Huayuan Zhu, Jinhua Liang, Miao Yi
exaly +3 more sources
Targeting XPO1 for fighting relapsed/refractory diseases: The research progress of XPO1 inhibitors
Bioorganic ChemistryXPO1 is an influential member of the nuclear transporter protein family. The proteins and RNA transported by XPO1 are related to the occurrence and development of many diseases, including refractory tumor diseases and various viral infectious diseases. XPO1 is upregulated in many malignant tumors and is associated with poor prognosis.
Ye-Qin, Li +4 more
exaly +3 more sources

